HC Wainwright Reiterates Buy Rating on Krystal Biotech
HC Wainwright reiterated its Buy rating on Krystal Biotech and maintained a $361 price target. The target implies 9.2% upside from the Oct. 14 close of $330.69.
HC Wainwright reiterated its Buy rating on Krystal Biotech and maintained a $361 price target. The target implies 9.2% upside from the Oct. 14 close of $330.69.